Executive Summary

The global medical technology (medtech) landscape is undergoing structural transformation, driven by shifts in pricing dynamics, care delivery models, supply chain configuration, clinical pathways, and digital integration. For Europe, a region that hosts a significant share of the world’s medtech innovation and manufacturing, these changes carry strategic weight. This article examines five trends identified in Clarivate’s Medtech Trends to Watch in 2026 and analyzes their implications for European competitiveness, investment, and industrial policy. From the expanding influence of China’s volume-based procurement (VBP) to the rise of platform-based competition, European medtech companies and policymakers must adapt to a market that is increasingly defined by global interconnectedness and technological convergence.

Introduction

Europe has long been a cornerstone of the global medical technology industry, home to leading firms, innovative startups, and robust research ecosystems. However, the forces reshaping the sector in 2026 are not confined by national borders. Pricing pressures emanating from China, the accelerating migration of procedures to outpatient settings, the imperative of supply chain resilience, the clinical impact of GLP-1 therapies, and the emergence of integrated technology platforms are collectively redefining the competitive landscape. For European stakeholders, these trends present both challenges and opportunities, demanding strategic foresight and policy alignment.

Main Analysis

1. China’s VBP Expansion: Global Pricing Pressures and European Competitiveness

Mainland China’s national volume-based procurement programs have evolved into a formidable market-structuring mechanism. The latest rounds incorporate more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers, as highlighted in Clarivate’s analysis. For European medtech companies, the implications extend well beyond the Chinese market. Global pricing expectations are increasingly shaped by these developments, compressing margins and forcing multinationals to reassess portfolio strategies.

European firms must navigate a dual challenge: maintaining access to China’s vast healthcare market while protecting their global value propositions. The VBP environment is accelerating domestic innovation in China, which may eventually compete with European exports in third-country markets. Strategic responses include diversifying revenue streams, focusing on differentiated technologies, and exploring partnerships that localize production in China without compromising intellectual property.

2. Outpatient and Ambulatory Care Shifts: Reorienting European Procedure Strategies

The shift from hospital-based procedures to outpatient and ambulatory surgical centers (ASCs) is a defining trend in the United States, as evidenced by recent CMS rulemaking. While Europe’s care delivery models differ across member states, the underlying trajectory toward lower-cost, less-invasive care is equally relevant. The expansion of ASC-eligible procedure lists, including higher-acuity interventions like cardiac ablation, reflects a broader movement toward cost efficiency and patient-centered care.

For European medtech companies, this shift demands adaptation in commercial models, product design, and value communication. Devices must be optimized for outpatient settings, with emphasis on ease of use, safety, and faster recovery. Providers across Europe are increasingly seeking solutions that enable same-day discharge and reduce hospital stays. Companies that anticipate these needs—particularly in orthopedics, general surgery, and cardiology—will be better positioned to capture growth.

3. Supply Chain Pressures: Reshaping Europe’s Manufacturing Strategy

Global trade tensions, tariff exposure, and geopolitical instability have elevated supply chain resilience from a logistics concern to a strategic imperative. Clarivate’s report underscores how manufacturers are diversifying sourcing, rebalancing production footprints, and leveraging technology to buffer volatility. For Europe, this has particular resonance given the region’s heavy reliance on imports for critical components and raw materials.

The COVID-19 pandemic highlighted Europe’s vulnerabilities in medical supplies, prompting initiatives like the European Health Emergency Preparedness and Response Authority (HERA). In 2026, medtech companies are reevaluating their manufacturing geography, with many considering nearshoring or reshoring to reduce dependency on Asia. Europe’s industrial policy, including its focus on strategic autonomy and the Green Deal, is creating incentives for sustainable and resilient production. However, the cost implications are significant. European firms must balance competitiveness with resilience, potentially through multi-region manufacturing networks and digital supply chain management.

4. GLP-1 Therapies: Disrupting Metabolic Care Pathways Across Europe

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management is having ripple effects across medtech categories. As Clarivate notes, while bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s are changing referral patterns and influencing demand for related devices. In Europe, where obesity rates are rising, this trend is particularly impactful.

European medtech companies involved in obesity treatment, diabetes care, sleep apnea, and cardiovascular monitoring must assess how patient behavior is shifting. The supply of GLP-1 medications is expanding, and their role is likely to grow, potentially reducing demand for certain bariatric procedures while increasing the need for diagnostic and monitoring technologies. Clinical pathways may also evolve, with patients using GLP-1s earlier in their treatment journey. Companies should invest in understanding these dynamics and adapting their product portfolios accordingly.

5. Enabling Technologies: Platform-Based Competition and Europe’s Innovation Opportunity

Enabling technologies—robotics, imaging, navigation, and digital workflow software—are no longer adjuncts but central to medtech differentiation. Clarivate’s analysis highlights the emergence of platform architectures that anchor entire service lines and unlock data-driven value propositions. Europe, with its strong tradition of engineering excellence and digital innovation, is well-positioned to lead in this area, provided it fosters an environment conducive to cross-sector integration.

European companies are increasingly investing in open platforms that enhance flexibility and interoperability, aligning with the EU’s push for digital healthcare interoperability. However, competition is intense, with major players from the United States and Asia investing heavily in end-to-end ecosystems. To maintain competitiveness, European medtech firms must forge partnerships across technology domains, leverage the region’s strengths in research, and ensure regulatory frameworks support innovation. The EU’s recently adopted Health Technology Assessment (HTA) regulation and the European Health Data Space are pivotal enablers.

Business Impact

These trends collectively reshape the strategic landscape for European medtech companies. Portfolio management requires greater agility, with a focus on high-growth areas such as outpatient therapies, digital platforms, and metabolic care. Investment in supply chain resilience and manufacturing flexibility is no longer optional but essential for long-term viability. China’s pricing pressures necessitate innovative market entry strategies, potentially including local partnerships. The shift to outpatient care implies a renewed focus on health economics, proving value through improved patient outcomes and cost efficiency. Moreover, the integration of enabling technologies creates opportunities for new revenue models, including software-as-a-service and data monetization.

For investors, these trends signal where value is likely to accrue. Companies that adapt proactively—diversifying geographically, embracing digital platforms, and navigating clinical shifts—may outperform sector peers. Conversely, those slow to respond may face margin compression and market share erosion.

European Perspective

Europe’s medtech ecosystem is deeply intertwined with the global market, but its regulatory, political, and economic context brings unique considerations. The EU’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have increased compliance burdens, potentially affecting innovation and competitiveness. At the same time, Europe’s focus on strategic autonomy, as articulated in various industrial policy initiatives, underscores the importance of maintaining critical manufacturing capacities. The Green Deal adds an environmentally sustainable dimension to production processes, potentially altering cost structures and sourcing decisions.

Cross-border cooperation within the Single Market is vital. Fragmentation in procurement and health technology assessment can hamper the scale needed for competitiveness. Enhancing the European Health Data Space and harmonizing digital standards are steps in the right direction. Additionally, Europe’s strong science base and startup ecosystem provide a fertile ground for platform-based innovation, though access to scale-up funding remains a challenge compared to the United States.

Future Outlook

Over the next three to five years, the trends identified are likely to intensify. China’s VBP will continue to evolve, potentially expanding to more device categories and influencing global pricing benchmarks. Outpatient care will grow steadily, with technological advances enabling more procedures to be performed safely in ambulatory settings. Supply chain resilience will remain a priority, with Europe increasingly viewed as a location for localized production, especially for critical medical technologies. The GLP-1 effect is expected to deepen as new indications emerge, further reshaping metabolic care. In enabling technologies, we anticipate convergence between AI, data analytics, and surgical platforms, with Europe needing to invest heavily in digital infrastructure and AI research to remain competitive.

European policymakers and industry leaders must act decisively. Key priorities include streamlining regulatory pathways, fostering public-private partnerships, supporting SME innovation, and investing in skills and digital infrastructure. By aligning industrial policy with these global trends, Europe can strengthen its position as a leader in medtech innovation and manufacturing.

Conclusion

The medtech landscape in 2026 is defined by global interconnectedness and rapid technological evolution. For Europe, the imperative is clear: adapt strategically, invest in resilience and innovation, and leverage the region’s unique strengths in engineering, data, and healthcare. By understanding and responding to these five trends, European medtech companies and policymakers can navigate the complexities of the evolving market and ensure sustained competitiveness.

Key Takeaways

• China’s VBP expansion is compressing medtech pricing globally, necessitating portfolio reassessment and market access strategies.
• The shift to outpatient and ambulatory settings is altering procedure dynamics, requiring product and commercial model adaptation.
• Supply chain resilience has become a strategic priority, driving Europe to consider nearshoring and digital supply chain management.
• GLP-1 therapies are reshaping metabolic care pathways, impacting demand across bariatric surgery, diabetes, and cardiovascular devices.
• Enabling technologies are fostering platform-based competition, offering Europe an innovation opportunity if supported by coherent policy and investment.

Sources

• Clarivate. "5 Medtech Trends to Watch in 2026." https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026